A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Spinal Muscular Atrophy, Neuromuscular Diseases, SMA

In brief

This trial will study the efficacy and safety of taldefgrobep alfa as an adjunctive therapy for participants who are already taking a stable dose of nusinersen and/or risdiplam and/or have a history of onasemnogene abeparvovec, compared to placebo.

Key facts

Study ID
NCT05337553
Run by
Biohaven Pharmaceuticals, Inc.
People needed
269
Starts
2022-07-06
Expected to finish
2027-12-01
Last updated by the study team
2026-06-01

Who can join

Age: 4 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.